Key result
Autologous adipose stem cell transplantation shows zero adverse events and improves stroke scores at 6 months.
Randomized trial reveals improved neurological function without adverse effects in chronic ischemic stroke, indicating the safety of autologous stem cell grafting.
cells). The primary endpoints of safety evaluation included adverse events, over a 6 months post-implantation period. The secondary endpoints included improvements in neurological functions. Evolutional change of brain parenchyma was also followed with magnetic resonance imaging (MRI). All three participants improved significantly at 6 months follow-up. The extent of improvement from pre-treatment was: National Institutes of Health Stroke Scale improved 5-15 points, Barthel Index: 25-50 points, Berg balance scale 0-21 points and Fugl-Meyer modified sensation 3-28 points. All three patients had signal change along the implantation tract on MRI one month after surgery. There is no related safety issue through 6 months observation. Clinical measures of neurological symptoms of these patients with chronic stroke improved at 6 months without adverse effects after implantation of autologous adipose-derived stem cells (GXNPC1), which might be correlated with post-implantation changes on brain MRI. Clinical Trial Registration-URL: https://clinicaltrials.gov/ct2/show/NCT02813512?term=ADSC&cond=Stroke&cntry=TW&draw=2&rank=1 Unique identifier: NCT02813512.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2021) studied chronic ischemic stroke (n=3). Intracerebral transplantation of autologous adipose-derived stem cells (GXNPC1) was evaluated on Adverse events over a 6 months post-implantation period. Intracerebral transplantation of autologous adipose-derived stem cells resulted in 0 adverse events and improved NIH Stroke Scale scores by 5-15 points across 3 patients at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: